CliffBio
small molecule

XYOSTED (AUTOINJECTOR)

TESTOSTERONE ENANTHATE

Loss of exclusivityAugust 2038latest FDA-listed patent expiry
CompanyAntares Pharma Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameXYOSTED (AUTOINJECTOR)
Active ingredientTESTOSTERONE ENANTHATE
Strength50MG/0.5ML (50MG/0.5ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusRX

Listed patents

PatentExpiresType
10646495August 2038product
9950125September 2036product
9744302November 2035product
11191908October 2035product
12629483August 2035product
11813435February 2035product
10912782February 2035product
10238662February 2035product
11160751October 2034product
10881798February 2034product
10821072June 2033product
11844804June 2033use U-2418
10905827August 2031product
11446440August 2031product
10357609August 2031product
10279131July 2031product
11497753March 2030product
8021335October 2026product
8562564January 2026product
11446441January 2026product
9533102January 2026product
9180259January 2026product
9629959January 2026product
10478560January 2026product

More from Antares Pharma Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XYOSTED (AUTOINJECTOR) patent cliff — loss of exclusivity August 2038 | CliffBio